ADVA launches embedded timing solution for third-party hardware
2.11.2021 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today introduced its OSA 5400 SyncModule™ embedded timing solution, enabling technology suppliers to easily integrate precise synchronization into their hardware. The M.2 form factor module offers equipment vendors a way to simply and cost-effectively add crucial timing capabilities with key functionality into their switches, routers, open compute servers and other IT devices. Featuring GNSS, PTP and NTP engines as well as comprehensive PTP and GNSS monitoring and assurance functionality, the OSA 5400 SyncModule™ empowers third-party companies to leverage the unique expertise of ADVA’s Oscilloquartz synchronization specialists. The solution will provide a major boost to suppliers of mobile infrastructure and white box vendors. It will be key for enabling assured sub-microsecond timing in public and private networks as well as critical infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102005094/en/
ADVA’s new timing module enables technology manufacturers to easily embed synchronization capabilities into their devices (Photo: Business Wire)
“Our OSA 5400 SyncModule™ brings something completely new and very valuable to the market. For the first time, third-party technology manufacturers will be able to embed the most advanced synchronization capabilities into their designs and easily control them with our Ensemble Sync Director or their own management system,” said Gil Biran, general manager, Oscilloquartz, ADVA. “With our OSA 5400 SyncModule™, we’re extending the disaggregated approach to building networks into the area of synchronization. The integrated solution gives vendors the ability to instantly inject the most advanced, highly accurate and fully assured timing into their hardware platforms. As our solution utilizes the widely applied, standardized M.2 interface, integration is simple. It can also easily be added to existing designs.”
The trend towards network disaggregation is accelerating innovation and expanding the market for customers. This does, however, create a challenge for technology suppliers when it comes to synchronization. Now, the OSA 5400 SyncModule™ is filling that gap. The low-power M.2 module gives vendors of emerging technologies, such as open RAN and next-generation data center hardware, the ability to quickly harness the benefits of an integrated GNSS receiver, PTP, NTP and assurance engines, as well as full sync management functionality. Featuring multiple interface options for easy integration, the OSA 5400 SyncModule™ comes with an open API for simple configuration. It can also be managed by ADVA’s proven Ensemble Sync Director management system for complete control of the timing infrastructure.
“Cost-effective and hassle-free, our new embedded timing solution brings highly precise and assured synchronization to a whole new market. For companies who are suppliers of 5G RAN hardware or open compute servers, our OSA 5400 SyncModule™ offers major value,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Vendors like those, who are not necessarily experts in network timing, now have the opportunity to instantly pour all of our synchronization know-how into their solutions. And that enables customers to choose the ideal components for their specific needs complete with the best available timing.”
Watch this video to learn more about the OSA 5400 SyncModule™: https://youtu.be/iPUl_n0dvJU.
Further information is also available in these slides: https://adva.li/osa-5400-syncmodule-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005094/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
